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Introduction and objectives: Several trials have reported early supe-
riority of stenting over balloon angioplasty (POBA), yet long-term data are
sparse. The goal of this study was to contrast long-term clinical outcomes
and costs of these two treatment options.
Methods: Consecutive patients undergoing POBA or stenting of the
native femoral/popliteal arteries from January 2002 to May 2009 were
included. Patients were divided into two groups, PTA alone or stenting.
Study end points included actuarial 5-year primary patency (using strict
criteria of any hemodynamic change regardless of symptoms or reinterven-
tion), 5-year limb salvage, 5-year survival, and hospital cost.
Results: During this period, 815 primary procedures were performed,
511 POBA and 304 stenting. The mean follow-up duration was 33 months
(range, 0-98 months). Similar demographics were observed between two
groups. Treatment indications and TASC status are reported in the Table.
There was no difference in overall 5-year primary patency (POBA, 28% 
4%; stenting, 24%  6%; P  .31), nor was there a difference in 5-year limb
salvage in critical limb ischemia (CLI) patients (POBA, 80% 4%; stenting,
75%  10%; P  .18). There was no difference in 5-year survival in
claudicants (POBA, 71%  6%; stenting, 76%  6%; P  .65) or CLI
(POBA, 29%  5%; stenting, 36%  10%; P  .4). Procedural cost of
stenting was 60% more than POBA (P  .001) regardless of treatment
indications. When used for claudication, stenting added an additional 40%
(P  .001) to the hospital cost compared with POBA.
Conclusions: Long-term outcomes between POBA and stenting were
equivalent when stratified by indications. Stenting added significantly to
overall costs. These data support a posture of selective stenting in the
treatment of superficial femoral/popliteal lesions.
Table. Treatment indications and TASC status
Variable POBA Stents P
No. (%) No. (%)
Patients, total 511 304
Indications
Claudication 303 (59) 221 (73) .02
CLI 210 (41) 86 (28) .02
TASC
TASC A 149 (29) 59 (19) .05
TASC B 318 (62) 168 (55) 0.3Table. Continued.
Variable POBA Stents P
No. (%) No. (%)
TASC D 19 (4) 29 (10) .02
Mean  SD Mean  SD
5-year outcomes
Overall primary patency 28%  4% 24%  6% .31
CLI limb salvage 80%  4% 75%  10% .185
Claudication survival 71%  6% 76%  6% .65
CLI survival 29%  5% 36%  10% .405
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Introduction and objectives: The management of chronically oc-
cluded lower extremity (LE) arteries is one of the more challenging issues for
endovascular therapy. Not only is the procedure more complicated, the
long-term patency has been a concern. We reviewed our prospectively
maintained database to evaluate the long-term effectiveness of the endovas-
cular treatment of chronic total occlusions (CTOs).
Methods: We reviewed our prospectively maintained LE database
between March 2004 and April 2010. All CTO lesions were evaluated.
Treatments included angioplasty (PTA), atherectomy (Ath), or PTA with
stent (PTAS). A dedicated research team independently evaluated the
preprocedure, intraprocedure, and postoperative angiographic and nonin-
vasive duplex imaging, as well as clinical follow-up data. Primary (PP),
primary assisted (PAP), secondary (SP) patency, and limb salvage (LS) were
calculated.
Results:A total of 2800 lesions were treated in 1233 patients, with 688
CTOs identified. Lesions were divided by location SFA (n 193), popliteal
(n  67), tibial (n  217), and multilevel (n  211). PP, SP, and LS at 2
years were 40.1  6.7, 74.9  6.1, and 81.1  7.3 for SFA lesions treated
with PTAS and 44.0  7.0, 79.9  5.3, and 90.5  6.7 for Ath,
respectively. Tibial vessel PP, SP, and LS were 51.1  6.2, 56.2  6.2, and
66.8  7.1 for PTA and 50.2  5.6, 66.5  5.1, and 76.5  5.9 for Ath
(Tables I, II and III)
Conclusions: The endovascular management of CTOs has excellent
2-year results for SP and good PP and PAP. PTA alone in the SFA has
relatively poor long-term results and should be discouraged. Although
reintervention maybe required, endovascular therapy should be consideredTASC C 33 (6) 52 (17) .002 the primary therapy for CTOs and surgical bypass reserved for failed endo-
vascular therapy.
Table I. Patency of SFA CTO
Patency variable No. 6 mo 12 mo 18 mo 24 mo
Primary patency
PTA  stent 97 83.0  4.2 51.2  6.3 42.8  6.5 40.1  6.7
PTA 21 64.6  10.8 53.9  11.4 42.4  11.5 30.3  11.0
Ath 75 77.7  5.1 56.2  6.5 49.5  6.8 44.0  7.0
P (PTAS vs PTA) .044 .675 .621 .402
P (PTAS vs Ath) .483 .952 .964 .972
P (PTA vs Ath) .137 .509 .413 .270
Primmary assisted patency
PTA  stent 97 86.7  3.8 69.3  5.8 64.3  6.4 61.1  6.8
PTA 21 64.6  10.8 53.9  11.4 47.9  11.6 35.9  11.4
Ath 75 82.1  4.7 67.6  6.1 63.1  6.4 55.2  7.1
P (PTAS vs PTA) .012 .076 .076 .032
P (PTAS vs Ath) .538 .643 .640 .515
P (PTA vs Ath) .045 .118 .115 .077
Secondary patency
PTA  stent 97 91.7  3.0 93.1  4.6 78.0  5.5 74.9  6.1
PTA 21 69.7  10.4 64.3  10.9 57.9  11.5 45.0  12.0
Ath 75 84.6  4.5 84.6  4.5 79.9  5.3 79.9  5.3
P (PTAS vs PTA) .004 .027 .030 .010
P (PTAS vs Ath) .578 .948 .975 .814
P (PTA vs Ath) .020 .021 .026 .004
